Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Dianthus Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• On a quarterly basis, Operating Leases fell 12.98% year-over-year to $1.0 million in Q4 2025; TTM through Dec 2025 was $1.0 million, a 12.98% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 12.98% from the prior year.
• Operating Leases fell to $1.0 million in Q4 2025 per DNTH's latest filing, from $1.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $32.4 million in Q1 2022 and bottomed at $30000.0 in Q2 2024.
• The 4-year median for Operating Leases is $1.1 million (2025), against an average of $7.5 million.
• Across the five-year window, Operating Leases sank 99.05% in 2023 and soared 3630.0% in 2025, its largest moves.
• Year by year, Operating Leases stood at $438000.0 in 2022, then tumbled by 61.64% to $168000.0 in 2023, then surged by 597.02% to $1.2 million in 2024, then fell by 12.98% to $1.0 million in 2025.
• Per Business Quant, the three latest DNTH Operating Leases figures stand at $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025).